Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408314 · ClinicalTrials.gov registry record · NA
The PediQUEST Response Intervention Study
A NA study of Advanced Cancer, sponsored by Joanne Wolfe, MD, MPH.
- Completed
- Registry status
- NA
- Development phase
- 196
- Enrollment target
- 6
- Study locations
NCT03408314: Completed NA study of Advanced Cancer, sponsored by Joanne Wolfe, MD, MPH.
NCT03408314 is a NA study of Advanced Cancer that has completed, run by Joanne Wolfe, MD, MPH. The registered enrollment target is 196 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (20% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03408314, a NA study of Advanced Cancer, has completed, sponsored by Joanne Wolfe, MD, MPH.
- COMPLETED
- Registry status
- NA
- Development phase
- 196 participants
- Enrollment target
- 6
- Study locations
Study Summary
PediQUEST Response proposes a new system of care that expects to improve quality of life in children, adolescents, and young adults with advanced cancer and their parents. The investigators want to learn whether patients that are cared for using PediQUEST Response do in fact feel better than those receiving usual care. National recommendations call for early palliative care (PC) integration for seriously ill children to ease suffering, however, very few randomized controlled trials (RCTs) have evaluated whether PC improves child and family outcomes. In prior work, the investigators developed the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST/PQ), a software that collects electronic Patient-Reported Outcomes (e-PROMS) and generates feedback reports. Now, the PI and research team developed PediQUEST Response (Response to Pediatric Oncology Symptom Experience). PediQUEST Response includes an enhanced PediQUEST system (web-based and with an App that allows to answer surveys and see reports), that is coupled with early integration of a palliative care consulting team (Response team). This dual strategy will help to standardize the family report of distress, which will be done through the PediQUEST system. It will also help standardize the providers' response to such distress, as providers will be specifically trained. Pilot work for PediQUEST Response found it feasible, well received by families and oncologists, and potentially effective. Thus, the overall goal of this study is to conduct a RCT of PQ Response versus usual care at four large pediatric oncology centers among 136 children ≥2 years old with advanced cancer. Hypotheses include a) children receiving the intervention will have better (higher) quality of life scores b) parents of children in the intervention group will report better state-anxiety, depression and symptom-related stress scores, and c) intervention group families will demonstrate higher levels of activation.
Primary Outcome
The primary outcome was child Pediatric Quality of Life Inventory 4.0 (PedsQL) total score, analyzed by respondent: (a) parent-reported for all enrolled children (n=154), and (b) child-reported (if 5 years of age or older) (n=103). PedsQL total scores are calculated as the average of the 23 items that integrate the tool. Scores range from 0-100 (100 is excellent quality of life). A score of \<70 is considered fair/poor quality of life. Intervention effect was measured as the mean difference bet
Conditions Studied
Interventions
- OTHER PediQUEST Response
- OTHER Usual Cancer Care
Study Locations (6)
Massachusetts
- Boston Children's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Children's Hospital - Houston
Washington
- Seattle Children's Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2022-09-14 |
| Phase | NA |
What the finished NCT03408314 record still lists
NCT03408314 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which PediQUEST Response is the first listed.
NCT03408314 lists 6 locations in 5 states (Massachusetts, Illinois, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT03408314 about?
NCT03408314 is a clinical study titled "The PediQUEST Response Intervention Study". PediQUEST Response proposes a new system of care that expects to improve quality of life in children, adolescents, and young adults with advanced cancer and their parents. The investigators want to learn whether patients that are cared for using PediQUEST Response do in fact feel better than those r...
What is the current status of trial NCT03408314?
This trial is currently completed. It is a NA study. The enrollment target is 196 participants. The study started on 2018-03-01. Estimated completion is 2022-09-14.
What conditions does trial NCT03408314 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT03408314?
The interventions under investigation include: PediQUEST Response (OTHER), Usual Cancer Care (OTHER).
Who is sponsoring clinical trial NCT03408314?
This trial is sponsored by Joanne Wolfe, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03408314 being conducted?
This trial has 6 study locations across Illinois, Massachusetts, Pennsylvania, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03408314's enrollment target sits among peer trials
196 34th of 122 higher than 89 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
RECRUITING · NA
-
Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services
RECRUITING · NA
-
ALIGN for Older Adults With Cancer in SNFs
RECRUITING · NA
-
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI